                                                                                                                   
                                                   UNITED STATES                                                   
                                                                                                                   
                                                                                                                   
                                        SECURITIES AND EXCHANGE COMMISSION                                         
                                                                                                                   
                                                                                                                   
                                               WASHINGTON, DC 20549                                                
                                                                                                                   
                                                                                                                   
                                                     FORM 8-K                                                      
                                                                                                                   
                                                  CURRENT REPORT                                                   
                                                                                                                   
                                      Pursuant to Section 13 or 15(d) of The                                       
                                                                                                                   
                                          Securities Exchange Act of 1934                                          
                                                                                                                   
                                 Date of report (Date of earliest event reported):                                 
                                                                                                                   
                                                  April 25, 2024                                                   
                                                                                                                   
                                                 Johnson & Johnson                                                 
                                                                                                                   
                              (Exact name of registrant as specified in its charter)                               
                                                                                                  
  New Jersey                         1-3215                     22-1024240                        
  (State or Other Jurisdiction of    -Commission File Number    -IRS Employer Identification No.  
  Incorporation)                                                                                  
                                                                                                  
                           One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933                            
                                                                                                                   
                                     (Address of Principal Executive Offices)                                      
                                                                                                                   
                        Registrant's telephone number, including area code ( 732) 524-0400                         
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation
of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17

CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17

CFR 240.13e-4(c))
                            Securities registered pursuant to Section 12(b) of the Act:                            
                                                                                                    
  Title of each class               Trading Symbol(s)    Name of each exchange on which registered  
  Common Stock, Par Value $1.00     JNJ                  New York Stock Exchange                    
  0.650% Notes Due May 2024         JNJ24C               New York Stock Exchange                    
  5.50% Notes Due November 2024     JNJ24BP              New York Stock Exchange                    
  1.150% Notes Due November 2028    JNJ28                New York Stock Exchange                    
  1.650% Notes Due May 2035         JNJ35                New York Stock Exchange                    
                                                                                                    
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the
Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2
of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section
13(a) of the Exchange Act. ☐

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
On April 25, 2024, the Board of Directors (the “Board”) of Johnson & Johnson (the “Company”) approved and adopted
amended and restated by-laws of the Company (the “Amended and Restated By-Laws”), effective as of such date. Among
other updates, the Amended and Restated By-Laws:
• update and expand the procedural and informational requirements for a shareholder request to call a special
meeting;

• update provisions relating to the adjournment, postponement and conduct of shareholder meetings, including
memorializing the Chair and Board’s authority to adjourn or postpone meetings and set forth rules for the conduct
of meetings;

• clarify the applicable voting standard at meetings of shareholders for matters other than the election of
directors, consistent with the New Jersey Business Corporation Act;

• update and expand the procedural and informational requirements for director nominations and other proposals
submitted by shareholders under the Company’s “advance notice” provisions, including updates to reflect the SEC’s
adoption of “universal proxy” rules as set forth in Rule 14a-19 under the Securities Exchange Act of 1934, as
amended;

• update and expand the procedural and information requirements for director nominations submitted by shareholders
under the Company’s “proxy access” provisions;

• clarify that, unless the Board otherwise designates, the Chief Executive Officer of the Company also serves as
the President of the Company;

• update the Company’s director and officer indemnification provisions; and

• make other non-substantive and conforming revisions and clarifications.
The foregoing description does not purport to be complete and is qualified in its entirety by reference to the full
text of the Amended and Restated By-Laws, a copy of which is attached as Exhibit 3.1 hereto and incorporated herein
by reference.
Item 5.07 Submission of Matters to a Vote of Security Holders.

(a) T he 2024 Annual Meeting of Shareholders of the Company was held on April 25, 2024.

(b) At the 2024 Annual Meeting of Shareholders, the shareholders:

• elected all 13 Director nominees named in the 2024 Proxy Statement to the Company ’ s Board of Directors;

• approved, on an advisory basis, the executive compensation philosophy, policies and procedures described in the
“Compensation Discussion and Analysis” section of the 2024 Proxy Statement and the compensation of the Company’s
executive officers named in the 2024 Proxy Statement, as disclosed therein;

• ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting
firm for the fiscal year 2024; and

• did not approve the shareholder proposal for a gender-based compensation gaps and associated risks.

The following are the final voting results for each of the four items voted on at the meeting.

1. Election of Directors:
                                                                                        
                         Shares For    Shares Against    Shares Abstain      Non-Votes  
  D. Adamczyk         1,656,623,584        18,925,478         4,373,721    338,170,891  
  M. C. Beckerle      1,663,236,710        12,988,890         3,697,183    338,170,891  
  D. S. Davis         1,637,607,236        38,041,198         4,274,349    338,170,891  
  J. A. Doudna        1,663,406,168        12,832,643         3,683,972    338,170,891  
  J. Duato            1,561,512,061       109,541,207         8,869,515    338,170,891  
  M. A. Hewson        1,631,542,950        44,419,702         3,960,131    338,170,891  
  P. A. Johnson       1,662,656,052        13,581,894         3,684,837    338,170,891  
  H. Joly             1,656,506,211        19,141,858         4,274,714    338,170,891  
  M. B. McClellan     1,661,933,030        13,974,677         4,015,076    338,170,891  
  A. M. Mulcahy       1,624,143,536        52,044,434         3,734,813    338,170,891  
  M. A. Weinberger    1,651,183,425        24,483,916         4,255,442    338,170,891  
  N. Y. West          1,666,853,163         9,240,391         3,829,229    338,170,891  
  E. A. Woods         1,665,190,129        10,460,172         4,272,482    338,170,891  
                                                                                        
2. Advisory vote to approve named executive officer compensation (Say on Pay):
                                                                        
  For                        Against       Abstained         Non-Votes  
  1,511,199,544.00    159,356,373.00    9,366,866.00    338,170,891.00  
                                                                        
3. Ratification of appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public
accounting firm for 2024 :
                                                                   
  For                        Against       Abstained    Non-Votes  
  1,896,186,129.00    117,320,388.00    4,587,157.00            0  
                                                                   
4. Shareholder Proposal - gender-based compensation gaps and associated risks:
                                                                        
  For                       Against        Abstained         Non-Votes  
  64,871,020.00    1,595,866,856.00    19,184,907.00    338,170,891.00  
                                                                        
Item 9.01 Financial Statements and Exhibits

(d) Exhibits
                                                                                                 
  Exhibit No.    Description of Exhibit                                                          
  3.1            Amended and Restated By-Laws, effective April 25, 2024                          
 ─────────────────────────────────────────────────────────────────────────────────────────────── 
  104            The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.  
                                                                                                 
                                                                                                                   
                                                    SIGNATURES                                                     
                                                                                                                   
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
                                                         
                                    Johnson & Johnson    
                                    (Registrant)         
  Date:    April 29, 2024    By:    /s/Marc Larkins      
 ─────────────────────────────────────────────────────── 
                                    Marc Larkins         
                                    Corporate Secretary  
                                                         
